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Objectives Molecular assays are now considered to be the ‘gold standard’ for assessment of human
cytomegalovirus (CMV) infection and disease in those at risk from severe associated clinical manifestations.
There is, however little consistency in the methods used in different centres. This study was undertaken to
compare different qualitative molecular-based approaches for assessment of CMV activation from latency in
samples from immunosuppressed transplant recipients.
Methods Nucleic acid amplification techniques based on the polymerase chain reaction (PCR) and nucleic
acid sequence-based amplification (NASBA) were undertaken for the assessment of CMV replication and
associated disease in immunosuppressed transplant recipients. Samples from 32 transplant recipients were tested
during this study using three molecular-based strategies: (1) detection of CMV DNA in whole blood extracts
(positive after a single round of PCR considered ‘high-level’ positive, N¼ 55); (2) detection of cell-free CMV
DNA in plasma (two methods, N¼ 55 for each); and (3) detection of late pp67 CMV mRNA after NASBA
(N¼ 51). Results using a commercial pp65 antigenemia assay were available for comparison from 40 samples.
Results Seven samples were positive for CMV by all methods and 36 were negative by all methods undertaken.
The other 12 samples gave discordant results using different molecular methods. The correlation between whole
blood ‘high-level’ PCR, NASBA for pp67 mRNA and antigenemia results was generally good. Results
presented show that plasma PCR results do not always correlate with methods utilizing whole blood as the
substrate and that inhibitors in these samples could be problematic. Whole blood PCR gave more positive results
than the other assays but use of a nested assay on whole blood or plasma led to detection of CMV in individuals
who had no other indicators of virus replication and who did not develop associated disease (low specificity).
Although the number of confirmed CMV disease episodes was low in this study, the problems of low positive
predictive value for sensitive, qualitative PCR assays was clearly demonstrated.
Conclusion Assays based on qualitative detection of viral nucleic acid may provide information useful for
management of CMV but caution is necessary when making comparisons between results using different
molecular strategies. It remains to be proven in large, comparative clinical studies in which the approach and
method give the best balance between sensitivity, specificity and clinical relevance for different patient groups.
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INTRODUCTION
Human cytomegalovirus (CMV) is a member of the herpesvirus
family. The virus is ubiquitous in the human population and
persists throughout life after primary infection. CMV infection
is associated with significant disease and may be life-threatening
in immunocompromised individuals [1]. Those at greatest risk
from CMV infection include human immunodeficiency virus
(HIV)-infected individuals, renal transplant recipients, patients
who receive stem cell harvests and bone marrow transplant
(BMT) recipients. Opportunistic CMV infection following
bone marrow transplantation is associated with particularly high
morbidity and mortality rates [2]. Traditional methods for
laboratory diagnosis of CMV infection include serology, virus
culture, modified culture (shell vial assay) and antigen detection.
Culture may take up to 21 days to produce a positive result and is
a relatively insensitive method, while serology results are diffi-
cult to interpret, especially in immunocompromised patients.
Rapid diagnostic CMV methods such as the pp65 antigenemia
assay and amplification methods based on polymerase chain
reaction (PCR) or nucleic acid sequence-based amplification
(NASBA) for detection of viral genome or mRNA are more
sensitive than traditional methods. Such methods may be used
to detect virus switch from latency to replication prior to onset
of disease. These methods may prove beneficial for monitoring
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‘at-risk’ individuals and make the use of pre-emptive therapy
possible. Equally important is the need to assess the value of a
negative result and its use in prevention of inappropriate use of
antivirals.
There is very little consistency in the molecular-based meth-
ods and strategies utilized by different centers for CMV screen-
ing and diagnosis in immunosuppressed patients. The aim of this
study was to evaluate different CMV molecular methods based
on polymerase chain reaction (PCR) and nucleic acid
sequence-based amplification (NASBA) and compare results
with those for a widely used antigenemia assay. Our purpose was
to assess whether methods based on different strategies for
determination of clinically relevant CMV activation from
latency give similar results for blood samples taken from those
at greatest risk from CMV-related disease.
MATERIALS AND METHODS
Study design
Blood samples from patients were submitted to the Department
of Virology (Cardiff Public Health Laboratory) for investigation
of possible CMV infection. Samples were sent for diagnostic
investigation because of clinical suspicion of CMV-related
disease. For the majority of patients, a single sample was taken
for investigation, although two or more samples were taken
from 12 patients. Each sample taken was associated with possible
CMV-related problems and thus represents a single diagnostic
investigation. The patients typically presented with a febrile
illness and other characteristics of possible CMV infection (e.g.
leukopenia). We compared results obtained by our currently
utilized diagnostic method (commercial pp65 antigenemia)
with PCR on whole blood and plasma using an ‘in-house’
nested PCR, a single-round plasma PCR followed by plate
hybridization and NASBA for CMV late (pp67) mRNA tran-
scripts. Although the study was undertaken primarily to com-
pare assays, the results were assessed in the context of clinical
outcome in order to identify which method or combination of
methods would give most useful information regarding the
prediction of CMV activation and disease. There were seven
documented episodes of confirmed CMV disease from six
patients in the study (five renal transplant recipients and one
bone marrow transplant (BMT) recipient). Confirmation of
CMV disease was based on clinical signs and symptoms, histo-
logy and response to antiviral therapy.
Patients and samples
In total, 55 blood samples from 32 patients (21 BMT recipients
and 11 renal transplant recipients) were analyzed during the
course of this study. In addition, blood samples from 10 healthy
individuals (with no recent history of CMV infection but four
of whom were CMV seropositive) were also tested as controls
for the sensitive molecular methods. Although the numbers of
patients and controls in this study were small, the intention was
to undertake multiple tests using different procedures on these
samples in order to be able to obtain comparative data. Donor
(D)/recipient (R) CMV serostatus was available for eight of the
11 renal transplant recipients (Dþ/Rþ, N¼ 3; Dþ/R–, N¼ 4;
and D–/R–, N¼ 1).
Blood samples
Buffy coat cells for antigenemia assay were prepared from
EDTA blood according to the manufacturer’s instructions
(DiaSorin, Saluggia (VC), Italy) as detailed below. For molecular
assays, 100mL of whole blood was added to 900mL of guanidine
lysis buffer (Organon Teknika, Boxtel, Netherlands) and plasma
was separated within 3 h of collection. Processed blood speci-
mens were stored at 80 8C until analysis.
Preparation of nucleic acid
Nucleic acid was extracted from whole blood or plasma using
the silica-based extraction method described previously [3].
Plasma samples were also boiled at a 1 : 10 dilution in a boiling
water bath for 10 min and immediately placed on ice to be
used in a nested PCR reaction (10 mL/first round, 50 mL PCR
mix).
Nested PCR
Details of the nested PCR have been published previously [4].
In brief, 10 mL of total extracted DNA (whole blood/plasma)
or 10 mL of diluted, boiled plasma were analyzed in a 50-mL
first-round PCR. After amplification, 1 mL of each first-
round product was added to the nested PCR mix in a total
volume of 25 mL. The outer set of primers used in the first-
round PCR reaction amplified a 150-bp region of the CMV gB,
while the inner primer set, used in the nested reaction, ampli-
fied a 100-bp region of the CMV gB. Primer sequences and
locations are given in Table 1 and were supplied high-perfor-
mance liquid chromatography (HPLC) purified (Oswel DNA
Service Ltd, Southampton, UK). Analysis of PCR products
(10 mL) was undertaken by electrophoretic separation on an
ethidium bromide-stained 2% agarose gel. Nested PCR results
were available for whole blood and plasma samples from 55
patients and 10 controls.
Single-round PCR followed by plate hybridization
In addition to the ‘in-house’ nested PCR, single-round PCR
with plate hybridization was performed on plasma extracts.
Single-roundPCRwasperformedasdescribedabove, except that
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the equivalent of approximately 50 copies of internal control
DNA as described previously [5] was incorporated into the PCR
mix in order to exclude the presence of any potential ampli-
fication inhibitors. The internal control was designed to have
the same primer binding sites and to produce the same size of
amplified product as the wild-type target. Wild-type sequence
was differentiated from internal control using CMV-specific
and internal control-specific probes at the plate hybridization
stage (Table 2).
Detection of PCR products was undertaken by DNA enz-
yme immunoassay using a commercially available kit according
to the manufacturer’s instructions (GEN-ETI-K, DiaSorin).
The CMV capture probe was used at a concentration of 0.1 ng/
mL, and the internal control probe concentration used was
0.5 ng/mL. The amount of internal control added to each PCR
reaction was pre-optimized in our laboratory to yield repro-
ducible positive results while not masking any wild-type CMV
signal that may be present [5]. The cut-off value was set at 0.15
absorbance units greater than the negative control (average cut-
off was 0.081þ 0.15 absorbance units). Single-round PCR
results with plate hybridization detection were available for
55 plasma samples from patients and 10 plasma samples from
controls.
NASBA for pp67 transcripts
NASBA for CMV late mRNA transcripts (pp67) was per-
formed as described previously [6–8] using a commercially
available kit (Nuclisens CMV pp67, Organon Teknika). Whole
blood extracts were analyzed for the target-specific sequence,
and an internal control sequence was coamplified with the
wild-type RNA. Following the manufacturer’s instructions,
detection of amplified products was undertaken using
electrochemiluminescence (ECL), and the presence of CMV
pp67 mRNA interpreted in the context of the internal control
signal. Valid NASBA results were available for 51 samples from
patients and 10 samples from controls.
Antigenemia assay
The early structural protein (pp65) of CMV was detected by
immunocytochemistry with peroxidase staining using a com-
mercially available kit (CMV-vue Kit, DiaSorin). The assay was
performed according to the manufacturer’s instructions. Briefly,
peripheral blood leukocytes were separated from fresh whole
blood, counted and spotted onto slides. Following incubation
with monoclonal antibodies directed against CMV pp65 and
subsequent incubation with HRP conjugate, cells were stained
with chromogen/substrate and visualized for typical nuclear
staining. If any cell gave a positive signal in a total of 1 105 cells
analysed, the result was considered positive. CMV antigenemia
results were available for 40 samples from patients, with two
samples giving equivocal results.
RESULTS
Analysis of all samples
A summary of results for all samples is given in Table 3. For the
purposes of this study, CMV activation was defined as any
evidence for virus replication, i.e. antigenemia-positive result,
NASBA-positive result, nested PCR-positive result on plasma
or first-round PCR-positive result on whole blood. There was
no evidence of such activation by any method in samples from
healthy controls. Of the 55 samples from patients with suspected
CMV disease, seven (from six patients) were positive by all
Table 2 CMVand internal control probe sequences used for detection of amplified products by plate hybridization
Target Reference Probe sequence 50 -30 (50 is biotin labeled)
CMVgB





Table 1 Primer sequences, references and expected product sizes for CMV nested PCR
CMVgBPCR Product size (bp) Primer sequence 5030 Reference
Round1 150 1. GAGGACAACGAAATCCTGTTGGGCA
2. GTCGACGGTGGAGATACTGCTGAGG
[10]
Round 2 100 3. ACCACCGCACTGAGGAATGTCAG
4.TCAATCATGCGTTTGAAGAGGTA
[7]
PCR, polymerase chain reaction.
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CMV methods undertaken (assay of boiled plasma excluded;
see below). Thirty-six samples were negative by all methods.
Positive and negative predictive values are given for each of the
assay approaches based on the confirmed disease episodes
(Table 3). Although the number of disease episodes for analysis
is low, the problem associated with the use of very sensitive,
qualitative PCR-based assays leading to a particularly low
positive predictive value is clear.
Antigenemia results
Of the 40 samples from patients tested for CMV pp65 antigen,
only six were positive. Thus this method was the least sensitive
of the approaches used for detection of CMV, and all
antigenemia-positive samples were also positive by the
molecular-based methods. Analysis of patients with confirmed
CMV disease indicated that the assay had a sensitivity of 67%
(4/6 disease episodes identified) and specificity of 96% (based
on correct results for 22/23 patients without confirmed
disease).
Analysis of whole blood by PCR and NASBA
Whole blood nested PCR was the most sensitive method for
detection of CMV activation, with 19 whole blood samples
having detectable CMV DNA after analysis by agarose gel
electrophoresis. Eleven of these 19 samples gave a band of
the appropriate size after a single round of PCR, suggesting that
they contained a higher CMV DNA load than those positive
only after two rounds of PCR. Detection of such ‘high-level’
CMV DNA in whole blood is used in some centers as an
indication of ‘clinically significant’ CMV activation. Seven
samples contained detectable CMV pp67 mRNA by NASBA,
and of these, six were also positive for ‘high-level’ CMV DNA
by whole blood PCR. A comparison of NASBA and whole
blood PCR results is given in Table 4. Analysis of patients with
confirmed CMV disease indicated that whole blood nested
PCR had a sensitivity of 100% (7/7 disease episodes identified),
as expected, but the specificity was only 69% (based on correct
results for 18/26 patients without confirmed disease). Whole
blood single-round PCR had a better specificity (88%) but did
not pick up all cases of CMV disease (sensitivity 86%, 6/7
disease episodes identified). On this small sample size, NASBA
had a sensitivity and specificity of 100%.
Comparison of methods for analysis of CMVDNA in plasma
Boiled plasma was found to be unsuitable for use in a single-
round PCR with plate hybridization due to significant variation
in the efficiency of amplification, with only one sample of the
55 tested giving a positive result for the internal control. It was
found that nucleic acid extracts from plasma gave interpretable
results in this assay, with amplification of the internal control
confirmed for all samples tested. Of the 55 samples from patients








No. testeda PPV NPV
Buffy coat from
whole blood
Antigenemia (pp65) HRP/chromagen 6/40 80 92
Silica extracted
whole blood
NASBA (pp67) Probe detection (ECL) 7/51 100 100
Single round PCR Agarose gel 11/55 67 96
Nested PCR Agarose gel 19/55 47 100
Silica extracted
plasma
Nested PCR Agarose gel 15/55 58 100
Single-round PCR Agarose gel 11/55 67 96
Single-round PCR hybridization (ELISA) 10/55 75 96
Boiled plasma Nested PCR Agarose gel 8/55 43 85
All methodsc 7/40
One or more methods 19/55
aSamples from10 healthy controls were tested by all methods except CMV pp65 antigenemia assay and are not included in the table. No positive results were
obtained for samples fromhealthy controls.
bBased on seven disease episodes confirmed in six patients for all except NASBA and antigenemia, which was based on six episodes in five or six patients,
respectively.Total possible episodes analyzed 33 for all except NASBA and antigenemia, whichwere based on 30 or 29 episodes, respectively.
cAll assays apart from PCRon boiled plasma included in this figure.
HRP, horse radish peroxidase; PCR, polymerase chain reaction; NASBA, nucleic acid sequence-based amplification; ECL, electrochemiluminescence; ELISA,
enzyme-linked immunosorbent assay; PPV, positive predictive value; NPV, negative predictive value.
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tested by this method, 10 samples gave an unequivocal positive
result. The average positive and negative signals obtained for the
single-round PCR with the plate hybridization method were
1.627 and 0.099 absorbance units, respectively.
Boiled and extracted plasma samples were also subjected to
nested PCR. It was clear from the results obtained that inhibi-
tion of the PCR was also a problem when boiled (non-
extracted) plasma was used in this assay. This is important to
note, since many samples (e.g. urine and amniotic fluid) can be
analyzed in a nested PCR with minimal preparation [5]. In-
house assays that do not incorporate an internal control may not
show up the problems of inhibition. The results for extracted
plasma in a nested PCR were much better than those for boiled
plasma and gave more positive results than the single-round
PCR with plate hybridization detection. This was as expected
from previous studies using these assays [4,5,9]. The endpoint
detection sensitivity for nested PCR by amplification of a
known concentration of control CMV DNA (Sigma Chemical
Co., Poole, UK) is 10 copies of CMV DNA [4,9]. Sensitivity
of single-round PCR with hybridization detection is 100
copies of wild-type CMV DNA [5].
A comparison of results for PCR-based assays undertaken on
plasma preparations is given in Table 5. All of the 10 extracted
plasma samples that were positive by single-round PCR with
plate hybridization were also positive by nested PCR. Addi-
tionally, nested PCR on plasma extracts identified five samples
that were not detected by the plate hybridization. Four of these
five additional positive samples did not give positive results for
CMV pp65 antigen or pp67 mRNA. Discrepancies between
nested PCR and the plate hybridization method may be due to
the low level of CMV DNA present in plasma, variable sample
inhibition and possible fracture of blood cells. The discrepant
samples were all positive for CMV DNA in whole blood after
two rounds of PCR and probably indicate that plasma is not as
‘cell-free’ as we would wish when using this sample to indicate
currently replicating virus. Analysis of patients with confirmed
CMV disease indicated that the plasma assays had sensitivities of
100%, 86% and 86% and specificities of 81%, 88% and 92% for
nested PCR, first-round PCR and PCR with hybridization
detection, respectively (analysis based on seven confirmed disease
episodes and analysis of 26 patients without confirmed disease).
Analysis of results and clinical outcome for individual patients
Of the 32 patients included in this study, 12 had more than one
sample sent for testing. One of these patients (CMV-seropo-
sitive individual post-BMT) showed a progressive change in
results, with nested PCR on whole blood being the first test to
show a positive result (patient A, Table 6). Samples were sent
from this patient because of a suspicion of CMV bowel disease,
but all other tests showed a negative result for CMVand at this
stage he was not put on antiviral therapy. NASBA for CMV late
pp67 mRNAwas positive before any of the other tests which are
thought to indicate significant replication of CMV. Subse-
quently, all tests became positive. Despite ganciclovir therapy
instigated 2 days before a positive antigenemia result, the patient
developed severe graft-versus-host disease (GVHD) and died.
This was the only BMT recipient in the study who had
confirmed CMV disease. Samples taken on days 42 and 50
post-transplant which were positive in some molecular assays
predicted disease in this patient at a time when a positive result
was not obtained using the commercial pp65 assay.
Two renal transplant patients were investigated on two
occasions (30 and 34 days apart) and they also showed changes
Table 5 Comparison of methods for analysis of CMVDNA in plasma
Plasma extract nested PCR Plasma boil nested PCR
þ  þ 
Single-round plasma PCR þ 10 0 6 4
with plate hybridization  5 40 2 43
PCR, polymerase chain reaction.
Table 4 Comparison of PCR results with pp67NASBA onwhole blood extracts
Whole blood first-round PCR Whole blood nested PCR
þ  þ 
NASBA (pp67) þ 6 1 7 0
 3 41 10 34
Only results valid for bothmethods are included in the table. PCR, polymerase chain reaction; NASBA, nucleic acid sequence-based amplification.
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in results. Duodenal biopsy showed histologic evidence of
CMV inclusions in one patient (patient B, Table 6) and reactive
inflammation with CMV inclusion in the other (patient C,
Table 6). Both patients were CMV seropositive prior to trans-
plant, and their donors were also CMV seropositive. Patient B
was treated only after the second sample was taken on day 55
and still responded to ganciclovir therapy. Thus in this patient,
all assays gave a positive result before antiviral treatment was
given. Patient C was given two courses of ganciclovir and had
confirmed CMV disease associated with both samples being
taken. Nine patients from whom more than one sample was
available were consistently negative for CMV by all methods
(not listed in Table 6).
Clinical follow-up of the patients in this study group con-
firmed that CMV was detected in all who had corroborating
pathologic evidence for CMV disease. Thirty-six patient sam-
ples showed no evidence of CMV activation by any method
tested, and none of these patients went on to develop CMV
disease. Nested PCR on whole blood and plasma identified
CMV DNA in eight and five samples, respectively, from
patients who did not develop any clinically confirmed CMV
disease. These results support the hypothesis that nested PCR is
highly sensitive and may pick up low-level CMV DNA in
patients where there is no adverse clinical outcome.
DISCUSSION
Cytomegalovirus has long been recognized as a major cause of
life-threatening complications in transplant recipients. There is
increased interest and perceived need for use of techniques that
will allow early detection of viral activation before any symp-
tomatology, making the use of pre-emptive therapy possible in
those at greatest risk of disease. Routine laboratory techniques
such as the commercial pp65 antigenemia assay employed in this
study are used to predict CMV activation, but results may be
difficult to interpret in immunosuppressed patients, particularly
BMT recipients, because of their neutropenia. We aimed to
assess the potential use of molecular-based methodologies for
measurement of CMV activation in the immunosuppressed
transplant population and correlate laboratory findings for
different assays. Blood samples from healthy controls did not
yield detectable CMV-specific DNA or mRNA following
amplification. Thus, although highly sensitive, the molecular
methods used in this study did not result in detection of low-
level latent CMV infection present in healthy immunocompe-
tent individuals.
Our study results suggest that, of the different assays we
employed, those using antigen or mRNA detection on whole
blood were most suitable for assessment of clinically relevant
CMVactivation. Detection of CMV ‘high-level’ cell-associated
genomic DNA by PCR (positive after a single round of
amplification) in extracts of whole blood gave good sensitivity,
but the positive predictive value for CMV disease was less than
that for the commercial pp65 antigenemia assay and NASBA.
Nested PCR for detection of CMV DNA in whole blood
proved oversensitive and gave more positive results for indivi-
duals who did not have any subsequent evidence for develop-
ment of CMV-related disease than anyother test. Some published
reports have suggested that quantification of cell-associated viral
DNA by PCR is useful, as the level of CMV DNA in blood is
related to the likelihood of development of CMV-related disease
[10]. Unfortunately, quantitative CMV methods are expensive
and laborious for regular screening of those at risk of CMV-
related disease. Laboratories relying on very sensitive nested
Table 6 Example results where patient samples were positive by one or more methods
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NA, not available; PCR, polymerase chain reaction; NASBA, nucleic acid sequence-based amplification.
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 179–186
184 Clinical Microbiology and Infection, Volume 7 Number 4, April 2001
PCR, while identifying all CMV cases, may overuse antivirals,
with the associated costs and clinical consequences in vulnerable
individuals. Such a strategy may be suitable for some patient
groups (e.g. recipients of matched unrelated bone marrow) but
not for all immunosuppressed transplant recipients.
The pp65 antigenemia test was found to be the least sensitive
method for assessment of CMV activation, although the assay
gave a better positive predictive value for identification of CMV
disease than whole blood and plasma qualitative PCR assays.
Since the antigenemia test is dependent on the type and quality
of cells available from a peripheral blood sample, results can be
unreliable or difficult to interpret for severely neutropenic
patients (particularly BMT recipients) [11].
In our study, detection of cell-free plasma CMV DNA did
not always correlate well with the methods that utilized cell-
based samples for assessment of viral activation. Our study
demonstrates plasma inhibitors of PCR amplification, as indi-
cated by the failure to amplify the internal control and false-
negative results in nested PCR when samples were not
extracted prior to analysis. Positive results in plasma may reflect
cell fracture and release of low-level CMV sequences into
plasma. Using a positive CMV-specific PCR on plasma as an
indicator of cell-free (and thus replicating) virus would identify
individuals with low-level CMV DNA which may not be clini-
cally relevant (whole blood nested PCR positive only).
Follow-up of patients in our study revealed that all those who
developed confirmed CMV-related disease were identified.
CMV antigenemia identified all patients who had evidence
of virus activation by molecular methods, but results for indi-
vidual samples were variable. There were no cases of confirmed
CMV disease in patients from whom blood samples yielded
wholly negative results by molecular methods and antigenemia
test.
Nucleic acid amplification methods are especially suitable for
detection of low-level virus replication. In order for any method
to be adopted for routine use, it should be sensitive, specific,
user-friendly, reproducible, cost-effective and have a good turn-
around time. The sample preparation method utilized in this
study [3] can be applied to whole blood or plasma. Whole blood
extracts prepared in this way are suitable for use in NASBA or
PCR. Detection of late pp67 CMV-specific mRNA by NAS-
BA should be indicative of replicating virus. This method has
not been widely evaluated to determine the possible benefits it
may offer above the approach of using PCR-based methods.
The few studies that have used this approach [6–8] noted the
high specificity of this assay. We found the method to be robust,
with excellent specificity and sensitivity in our patient groups.
The simplicity of the pp67 NASBA makes it feasible for use in
screening patients at risk from CMV-related disease. For analysis
of plasma samples, the approach of using single-round PCR
with plate hybridization detection seemed to be suitable for use
in routine diagnostic testing, as it offers good sensitivity and
rapid turn-around time for results. Also, the inclusion of an
internal control highlights any possible sample inhibitors. In
comparison to the nested plasma PCR approach, this assay is
characterized by a less time-consuming methodology and mini-
mizes the possibility of carryover contamination during transfer
of products from the first round to the second round. The
slightly reduced sensitivity compared with nested PCR may be
an advantage in some patient groups. The assay would pick up
fewer samples with clinically irrelevant levels of CMV while still
identifying those at risk from the severe clinical manifestations.
Although small in terms of patient numbers, the availability
of multiple assay results on each sample allowed us to provide
useful comparative data. The results from this study indicate that
different molecular strategies do not necessarily give the same
results. The discrepancies were not consistently related to the
time post-transplant. The need for sensitive (and probably mol-
ecular-based) methods for monitoring of CMV infection and
diagnosis of CMV disease in immunosuppressed patients is well
established. However, further research is required to perform a
systematic evaluation of these qualitative molecular-based
methods to define their role in monitoring and diagnosis of
CMV. A better understanding of the pitfalls and strengths of
different CMV-specific methods can only enhance our use of
such assays and inform the decision as to whether the more
expensive quantitative PCR-based approaches offer further
advances in patient management.
ACKNOWLEDGMENTS
The study was undertaken with the approval of the local ethics
committee. This studywas partly supported by the British Society
for Antimicrobial Chemotherapy. The authors would like thank
Organon Teknika Ltd for assistancewith the NASBA process, and
DiaSorin Ltd for advice concerning plate detection of PCR
products. We would also like to thank the renal and hematology
physicians for providing patient information, and diagnostic
laboratory staff for their assistance with the antigenemia assay.
REFERENCES
1. Britt WJ, Alford CA. Cytomegalovirus. In: Fields BN, Knipe
DM, Howley PM, eds. Fields Virology, 3rd edn. Philadelphia, PA:
Lippincott-Raven Publishers, 1996: 2493–2523.
2. Prentice HG, Kho P. Clinical strategies for the management of
cytomegalovirus infection and disease in allogenic bone marrow
transplant. Bone Marrow Transplant 1997; 19: 135–142.
3. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van
Dillen PME, van der Noordaa J. Rapid and simple method for
purification of nucleic acids. J Clin Microbiol 1990; 28: 495–503.
4. Fox JD, Brink NS, Zuckerman MA et al. Detection of herpesvirus
DNA by nested polymerase chain reaction in cerebrospinal fluid of
human immunodeficiency virus-infected persons with neurologic
disease—a prospective evaluation. J Infect Dis 1995; 172: 1087–90.
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 179–186
Kulkarni et al CMV molecular studies 185
5. Jones RN, Neale ML, Beattie B, Westmoreland D, Fox JD.
Diagnostic assay for detection of Cytomegalovirus DNA by plate-
hybridisation with an internal control. J Clin Microbiol 2000; 38: 1–6.
6. Blok MJ, Goossens VJ, Vanherle SJV et al. Diagnostic value of
monitoring human cytomegalovirus late pp67 mRNA expression
in renal-allograft recipients by nucleic acid sequence-based
amplification. J Clin Microbiol 1998; 36: 1341–6.
7. Blank BSN, Meenhorst PL, Mulder JW et al. Value of different
assays for detection of human cytomegalovirus (HCMV) in pre-
dicting the development of HCMV disease in human immunode-
ficiency virus-infected patients. J Clin Microbiol 2000; 38: 563–9.
8. Gerna G, Baldanti F, Middeldorp JM et al. Clinical significance of
expression of human cytomegalovirus pp67 late transcript in heart,
lung and bone marrow transplant recipients as determined by
nucleic acid sequence-based amplification. J Clin Microbiol 1999;
37: 902–11.
9. Mitchell SM, Fox JD, Tedder RS, Gazzard BG, Lightman S.
Vitreous fluid sampling and viral genome detection for the
diagnosis of viral retinitis in patients with AIDS. J Med Virol 1994;
43: 336–40.
10. Fox JC, Kidd MI, Griffiths PD, Sweny P, Emery VC. Longitudinal
analysis of cytomegalovirus load in renal transplant recipients using
a quantitative polymerase chain reaction: correlation with disease.
J Gen Virol 1995; 76: 309–19.
11. Ehrnst A, Barkholt L, Lewensohn-Fuchs I et al. CMV PCR
monitoring in leucocytes of transplant patients. Clin Diagn Virol
1995; 3: 139–53.
12. Darlington J, Super M, Patel K, Grundy JE, Griffith PD, Emery
VC. Use of the polymerase chain reaction to analyse sequence
variation within a major neutralizing epitope of glycoprotein B
(gp58) in clinical isolates of human cytomegalovirus. J Gen Virol
1991; 72: 1985–9.
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 179–186
186 Clinical Microbiology and Infection, Volume 7 Number 4, April 2001
